Does Methylene Blue Satisfy an Option in COVID-19 ARDS (2022)

Peer-Reviewed Study · Yella SHT, Yella SST, Sasanka KSBSK, et al. · 2022

Yella SHT et al., 2022: Single-patient case report of methylene blue given by humidifier in COVID-19 ARDS, reporting rapid improvement in oxygen saturation. One patient, no control.

Methylene blue resulted in a significant decrease in respiratory distress and a steep rise in Spo2. We suggest trying methylene blue as an additional intervention in COVID-related acute respiratory distress

Yella SHT et al., 2022: Single-patient case report of methylene blue given by humidifier in COVID-19 ARDS, reporting rapid improvement in oxygen saturation. One patient, no control. Study type: case report. N=1. Country: India. MB delivered via humidifier for 5 days alongside non-invasive ventilation and standard care; dose not stated in abstract. Funding/conflicts: not stated. Comparator: none. The paper's opening sentence ("Methylene blue is the only medicine that has been shown to reduce the excessive generation of reactive species and cytokines") is an assertion, not a trial result. Study type: case report.